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Smooth muck cell pmlilwation is cenlral to the procffs ofrestene 
sis. Attfmots to inhibit the events kadine to this omltfemlion have 
met with iMe swcess. In addition to& k&n antithmmbMic 
eifects, kepnrin aI54 has inbibitwy et%% on a& mwte rett 
pmttteratton. Thpse etTects appear to he unrelated to i(s antttoagw 
lrnt pmprties and are retained in low meleculw weigkt kepexin 
derivatives. Althoughtheuwfhetwieparin bras long as 18 to24 h ahrr 
coronary m@qdasiy in humans has nol prevented ~Ienosis, longer 
treatment periods have not been e. 
dose enoxawrin 110 mdke ll~l dav) for either 2 or 4 works had _ _. 
similar m&n luminal dinmeters bepore and lmmedlately after 
angtoplasly. At folkwup an.g@rapby, the mean lumtnd diame- 
ter was 0.82 t 0.17 mm for low dose enexwarln, LO4 + 0.20 mm 
for 2 week higk dose enoxsparin (p = 0.03 v&us mntml) and 
1.19 f 0.09 mm for 4 wook hick dose enowarin C = 0.0(11 
versus eontml). 
When defined av loss ol So% OI the initial gain achievd with 
sndotiasty, restenosts WBI found in all controt v&s. In the 2 
&kjllgh-dose enaxspartn group, only two of nine vessels hai 
resten& and in the 4 week hlgb dase garp, thrn d nine w&s 
had restennsls (p = 0.001 versuscoontml). Tkesl results show that 
atttiprdifelative kgenls welt 8s low mdeculkr weight keparin can 
inhibit restenosis n animal m&Is and sug8ti that they may be 
useful in humans. 
This study examines the oect of treatment with P tow mok-a 
ular weight heparin (enoxaparin) in a hypercbolertemlemic rabbit 
iliac artery mndel. Control rabbits had a utean iliac artery 
diameler of 0.70 t 0.06 mm, whiih increwd to 1.73 zt 0.09 tam 
alter ballwn angloplasty. At kdkX+Up angmphy 4 weeks I&, 
the mean vessel diameter was 0.56 * 0.12 mm. Animals treated 
with tow dose enoxaparin (t m&8 per day) lor 4 weeks and high 
Restenosis after coronary angioplasty occurs in 30% to 40% 
of cases (I). adding greatly to the morbidity and cost of the 
orocedure. The oathoeenesis of restenoais is not entirelv 1 
clear, but is presumably related to repair of the injury 
induced bv aneioolastv (2). This rewvnse is initiated bv 
platelet dcposiion and thrombus formation and results ih 
smooth muscle cell proliferation. The incidence of restenosis 
has remained remarkably constant over the past decade, 
despite attempts to reduce it by both phamncologic and 
mechanical means. Trials of aspirin (3). warfarin (4). nifed- 
ipine (5). diltiazem (6) and corticostemids 17.8) have had 
negative results. and the use of fish oil preparations has met 
with mixed success (9-l I). New technologies uch as lasers, 
stems and atherectomy devices have also not yet had any 
impact on the incidence of restenosis. 
As our understanding of the pathophysiolagy of resteno- 
sis has increased. new methods of inhibiting this process are 
suggested. Thus. the use of trapidil to block the effects of 
platelet-derived growth factor (12). antibodies to glycopro- 
win Ilblllla to prevent platelet aggregation (13) and colchi- 
tine to inhibit smooth muscle cell and leukocyte migration 
(14) we all under active investigation. Because smooth 
muscle cell proliferation appears central to the process of 
restenosis, the use ofan agent directed at the smooth muscle 
cell may circumvent some of these complex pathways lead- 
ing to the proliferative response. 
Enoxaparin. a low molecular weight derivative of hep- 
atitt. has antithrombotic properties similar to those of hep 
arin and has been shown to inhibit smooth muscle cell 
proliferation in vitro and in viva. We (14-18) and others (12) 
have used the atherosclerotic rabbit iliac artery as k model 
for coronary angioplasty and restenosis. The objective of 
this study was to determine if low molecular weight hepwin 
in the form of enoxaparin could reduce the intimal prolifer- 
ation seen after balloon angioplasty of obstructive lesions in 
the atherosclerotic rabbit. 
Methods 
P~tecol. Male New Zealand White rabbits weighing 
approximately 3 kg were studied. All procedures were 
performed under the guidelines of the Animal Welfare Act. 
The protocol was approved by the Institutional Animal Care 
and Use Committee a1 BosIon UniversiIy Medical Center. 
Bilateral iliac ufherosclerosis UUP induced in NPM 
Zealand Whiie r&ifs as in previous studies using this 
model (14-M). Animals were anesthetized with intravenous 
Pentothal and the distal femoral arteries were surgically 
exposed. A small arteriotomy was performed. and a 3F 
FogarIy catheter (American Edwards) was passed to a 
distance of 20 cm. The balloon was inflated to jus1 approxi- 
mate the arterial wall, and deendothelial:zaIion wad accam- 
plished by gently pulling the catheter down the iliac artery. 
To ensure complete removal of the endothelium. this pro- 
cess was repeated twice. The caiheter was then removed, 
the distal femoral artery ligated and the incision closed. All 
rabbits received 150,ooO U of penicillin by intramuscular 
injection and were placed on a diet consisting of rabbit chow 
supplemented with 1.5% cholesterol and 7% peanut oil. In 
earlier sIudies using this model, cholesterol levels ranged 
from I.500 to 2,OCIO mgidl (18). 
A&r 6 weeks fo ollms otherawlerosis IO dewlop. the 
presence of lesions was dacttmented. The rabbits were 
anesthetized with intravenous Pentothal. and the righI ca- 
rotid artery was surgically exposed. By means of a small 
nrterlotomy, a QF Swan-Ganz catheter (American Edwards) 
was advanced under Ruoroscopic guidance to a point 2 to 
4 CIII above the r.>rtic bifurcation. Meglumine diatrizoaie 
was hand injected at arate of 1 ml/s for 3 s. Cineanglographic 
images were obtained a: a rate of 30 framesis using a single 
plane Philips 6 in. (15.2 cm) image intensifier (North Amer- 
ican Philips Corporation) with a resolution of 3.13 line pairs.1 
mm. A L cm grid was positioned over the pelvis to allow 
correction for magnification. Angioplasty was performed at 
this time if a 59% to 95% iliac stenosis was present. as 
estimated from a still frame video image. 
For the angiaplasfy procedtrrL &is mid femoral artery 
was surgically exposed and an arteriotomv made. A 2.5 mm 
Gruentzig intraoperative transluminal angioplasty caIheIer 
(C. R. Bard) was passed retrograde until the balloon was 
across the site of greatest iliac artery stenosis. The balloon 
was inflated to a pressure of 5 atm for 30 s for a total of three 
inflations. The angioplasiy catheter was then withdrawn a d 
the result documented by repeat cineangiography using the 
Swan-Ganz catheter for dye injection as already described. 
with care taken to position the image intensifier a1 the same 
height. The catheters were Ihen removed. the an&s were 
ligated and 150,OCHl U of penicillin was administered intra- 
musculariy. 
All rnbbifr were maintained on the 1.5% cho/erfeml d&-r 
for 4 weeks, at which time fallor~-up angio~raphy II’PS 
per&rmed. With intravenous Pentothal anesthesia. the lef1 
carotid artery was surgically isolated and a 4F Swan-Canz 
catheter was introduced and advanced IO the aortic bifurca- 
tion under Auoroscopic guidance. Cineangiography was per- 
formed as just described. After euthanasia with an overdose 
of Pentothal. the iliac arteries were perfused with 10% 
buffered formalin at 80 to la0 mm Hg for 15 min through B 
cannula place& in the descending aorta. The entire aortoiliac 
trunk was removed in one piece. stripped of periadvential 
ConnccIive tissue and placed in a solution of 16% formalin 
for 272 h. After review of the an&rams to guide sampling, 
the appropriate sections of the treated iliac artery were 
removed and embedded in par&m. four sections of each 
arterial segment were siained with hematoxylin-rosin. van 
Gieson-elaslin and modified trichrome-fibrin stain%. 
Treatment groups. A Ioral of 31 rabbits were assigned to 
one of four treatment groups: control (n = III. 12 vessels): 
low dose enoxaparin (I mg/kg per day) given as a single daily 
subcutaneous injection. starhag the day of angioplasty and 
continuing for 4 weeks tn = 7. 10 vessels); high dose 
enoxaparin (IO mgkg per day) for 4 weeks (II = 7,9 vessels): 
and high dose enoxaparin (IO m&kg per day1 for 2 weeks 
(n = 7.9 vesselsr. All rabbits underwent follow-up anglog- 
raphy a1 4 weeks and were kiRed a1 that time. 
Analysis. Cineangiograms were viewed on a Vanguard 
projector (Vanguard Instrument Corporation1 independently 
by IWO experienced investigators who did no1 know the 
animals’ treatment. Luminal dieter was measured by 
using hand-held digital calipers (Brown and Shqe Manu- 
factoring1 to determine the most stenotic portion of the 
anery before. immediately after and at 4 weeks alter the 
anpioplasty procedure. True diameters were calculated by 
correcling for magnirication with the use of a 1 cm grid. 
Comparison of the average luminal diameter between Ireat- 
ment and control groups was made by a nonpaired Student’s 
I test. with a p value <0.05 accepted as aignifican1. Compar- 
ison of the incidence of reaenosis in rhe various groups was 
made by &i-square analysis. 
Hirrologic seerions were reviewed by at least IWO inves- 
tigators. and a consensus interpretation of the pathologic 
Rnding$ was made. Special attention was directed toward the 
degree of neointimal prolifemtion and the types of cells 
present, Care was taken to assess proliferation only in an 
area showing evidence of previous halloon inflalion. as 
manifested by splitting of the media or internal elaslic 
lamella. 
Results 
Anpiography 
Typical lesions are seen in Figure IA. with both 70% 
distal right and 66% mid left iliac stenoses. The immediate 
result of angioplasty is seen in Figure IB. with 26% stenoses 
at both sites. AI follow-up anglogmphy (Fig. IC). this 
control rabbit had severe restenosis to Bo% on the left and 
total occlusion on the tight. 
Normal vessel diicr. Tbe normal vessel mean diame- 
ter (measured just proximal to the point of maximal slenosis) 
was not different among the four treatment groups (mean 
value 2 SEM): 1.97 + 0.C9n1rnforIhecontrolgroup. 1.97 f 
0.08 mm for the 4 week low dose enoxaparin group, 1.77 ? 
Figure 1. A, Aonoiliac angiogram showing 70% right and @I% left iliac aRery 
stesoses (nrrws! before angioplaq. B. tmmediare postangioplarty angiogram 
showingsuccessful results in both zrterier. C, Followup a&gram at 4 weeks, 
showing total occlusion 01 the right iliac artery and 80% left iliac artery stenosis 
(PrrWS,. 
0.13 mm for the 4 week high dose enoxaparin group and I .9l 
i 0.09 for the 2 weik high dose enoxaparin group. The 
average luminal diameter of the normal vessel did not 
significantly change over the time of the study in any group. 
Preangioptasly stenosis severity. The luminal diameter at 
the point of most swere obstruction before anbioolasty was 
similar for all four groups (Tahlc I). ranging from 0165 5 
0.05 mm for the 4 week low dole enoxapari” group to 0.79 ? 
0.07 for the 2 week high dose enoraparin grooup. Mean 
sI”os~s severity was also similar, ranging from 56.6 f 3.5% 
for the 4 week high dose enoxapau” group to 66.7 r 2.4% for 
the 4 week low dose enoxaparin group. 
Results of angtoptasty. After angioplasty. similar success 
was achieved in all groups. Luminal diameter increased to 
1.73 ? 0.09 mm in the control group. 1.64 r 0.09 mm in the 
4 week lowdoseenoxapari” groupand 1.52 + 0.09 mm in the 
2 week high dose enoxapari” group (Table II. The result in 
the 4 week high dose enoxaparin group was slightly less 
optimal than in the control grwp (I.44 + 0.07 mm, p = 0.03). 
The residual stenosis after angioplasty ranged from I7 + 
3.6% for the control era”” to 23.4 + 4.2% in the 2 week high 
dose enoxapari” group; ‘“one of the treatment groups d:f- 
fered significantly from the control group. 
Four week follow-up angiognphy. At 4 week follow-up 
study. the average luminal diameter in the control group 
decreased to 0.56 + 0.12 mm. which was less than the 
original luminsl diameter before dilation. In the vessels 
treated with 4 weeks of low dose enoxaparin. the mea” 
luminal diameter was slightly improved at 0.82 -c 0.17 mm. 
In the high dose enoxaparin group. the mea” luminal diam- 
eter was sisnificantlv increased for both 4 weeks of treat- 
ment Ct.19 - 0.09. p’O.Wl)and 2 weeks of treatment(t.04 
i 0.20. p = 0.04). The me”” stenosis at follow-up angiogra. 
phy was 71.2 i 5.8% in the contml group versus 55.4 i 8.9% 
for 4 week low dose enoxaoarin wow. 43.3 5 I I.?% for ! 
week high dose cn”xapar& group lb = 0.03 venw the 
control crouol and 34.5 t 5.8% for 4 week high dose 
enoxapahn gioup lp = O.UUI vers”s the control gr”;Ql. 
Thr resuhs for individnml wssels in the ronmrol pnmp m 
shown in Figaro 2. The first point for each vessel is the 
diameter before angiaplasty. the middle point is the imme- 
diate result after angioplasty and the last point is the diam- 
eter at 4 week follow-up angiography. All vessels showed a 
successful acute result. At follow-up angiography. three 
vessels were totally occluded and all of the others rhowed 
some degree of restenosis. 
Figure 3 shmr.s the resrdr.xjbr w~.w’b trroted witIt 4 wrrks 
of high douse enoxrrprrri~r. Again. immediate SUCCESS was 
achieved in all vessels. However. at follow-up angiography. 
no total occlusions were xc” and only three vessels showed 
a major reduction in luminal diameter. 
Examining restenoris as adiscrete variable. the incidence 
of rcstenosis was significantly reduced by high dose enox- 
aparin. With restenosis defined as SO% IDS ofthe initial gain 
in luminal diameter achieved with angioplasty. I? of I? 
control vessels showed resrenosis. In contrast. only three of 
nine (p = O.UiM) 4 week hiih dose enoxaparin-treated vessels 
and two of nine tp = O.UOt) ? week high dose enoraparin- 
treated vessels had rcstcnosis by lhis definition. When 
Figwe 1. Individual umioal diitmctcrr for control reaelr before 
and immediately after angioQla,ty and al 4 week fotluu up an& 
raphy. 
rcstenosi, wa> defined as >5U% strnocis at follow-up angi- 
ogaphy. IO of 12 control ves& had rtstenosis. None of the 
high dose ? or 4 week-treated vessels had rcstenosis by this 
definition Ip = O.oOll. 
As expected from the angiogaphic results. the degree of 
ncointimal prolifcralion was less prominent in the high dose 
enoraparin-treated vessels than in conrrol vcsscls. Figure 4 
ahows a typical example of a control vcwcl. with a dense 
eosinophilic origind lesion with prominent areas of calcifi- 
cation. This original plaque was split by the angioplasty 
balloon. with disruption of the internal elastic lamella 
(stained black). The new lumen created by angioplasty has 
been complctciy replaced by a prolifernrive process. This 
consists Qredon;inandy of foam cells. with a sohstsntial 
am”““l of ehtracsllular matrix. 
In coohast. Figure 5 shows an example of a vessel treated 
wth high dose enoxaparin for 4 weeks. The original stenosis 
is seen as a relatively acellulararca with foci of calcitication. 
The clTccrs of hall”“” inflation ar: again present. with a split 
in this layer of tissue and disruption of rhe internal elastic 
tamclla. Compared with Figure 4. only a minimal prolibr- 
tive response is seen overlying this plaque. with preservation 
of a larger residual lumen. 
Figure 3. Individual luminal diameters for high dose 4 week cn”~- 
aprrin-trcaed vessels. 
Discussion 
Heparin for resteenosis. The use of heparin to prevent rest- 
enosis is attractive because of its known antithrombotic effect 
and more recenlly documented inhibitory effect on smooth 
muscle cell proliferation. Hepain has been used for >60 years 
to prevent thmmbosis. It exerts its effect by binding to and 
incrwsing the activity of the physiologic oagulation inhibitor 
antithrombin 111 (19). After a conformational change in this 
inhibitor. the heparin-antithmmbin 111 complex binds to factor 
Xa and thrombin tfactor Ila). Only about 30% to SW of 
heparin molecules in commercial heparin preparations have 
this antithmmbic effect (20). which appears to be hiihly related 
to the degree of sulfated residues (21). 
The ontithromboric properrie.! of heparin ore ihe bnsisfor 
irs rmrinr NSP in rmgioplart~: intimal dissection is a potent 
stimulus for platelet deposition, thrambus formation and 
abrupt vessel closure WZS). Additionally, organization of 
mural thrombus over a period of weeks can result in ather- 
osclerosis in nornnlipemic rabbits (26) and may contribute 
to restenosis in experimental models of angioplasty (15). 
This may occur either by incorporation of mural thrombus 
into the plaque or development of an occlusive thrombus 
that subsequently organizes. The inhibitory etRcts of hep 
win on thmmhus formation after angiaplasty were shown to 
be dose related but less potent than the effects of specific 
thmmhin inhibitors such as himdin (27). In that study. 72% 
of deeply injured arterial segments treated with 35 U/kg of 
heparin had mural thmmbus compared with only 10% of 
segments treated with 250 U/kg and none of those treated 
with bintdin. 
Low molecular weight heparin: enoxaparin. Heparin con- 
sists of a heterogeneous group of molecules with molecular 
Figure 5. Histologic section of an enoxaparin- 
treated vessel stained for elaslin Imagnification 
x 16,. 
weights ranging From Zoo0 to 40.000 daltons (average 
15,COO). Low molecular weight Fractions “fheparin l?.ooO to 
5,oW daltons) retain the at&Factor Xa activity. which some 
investieators (20) believe accounts for the antithromborx 
effect Gf heparin. The low molecular acight fractions have 
less of an lnhihitory effect on thrombin (Factor lla). This iz 
manifested by a l&k of elevation in the activated partial 
thromboplastin time and may translate into a lower bleeding 
risk. Enoxaparin is one of at least six low molecular weight 
heparin derivatives currentlv under investigation. It is ob- 
tained by the controlled de~olymerizat~on OF a benzyl ester 
of natural heomin and has a mean molecular weieht of 4.5uO 
daltons. The’elimination half-life “Fenoxaparin c 3 to 5 h in 
comparison with 0.6 h for nonfractionated heparin. When 
given as prophylaxis For elective hip surgery. enoxaparin in 
a dose of 30 me twice dailv sienilicantlv reduced the mci- 
deuce of deep Yenow thrdmbosis compared with placebo 
(10.8% versw 51.3%), with no increase in the rate of 
hemorrhage (28). Thus, the potential advantages of this 
agent over nonfractionated hepmin are II the potential For 
Fewer bleeding complications due to lack of inhibition of 
thrombin. and 2) more Favorable pharmacokinetics. 
Mechanisms of action. Both hewin and low molecular 
weight heparin derivatives have b&t shown to inhibit pro- 
liferation of vascular smooth muscle cells. I” a rat carotid 
artery injury model, Clowes and Kamovsky 129) first dem- 
onstrated the inhibitory effect of heparin on myointimal 
thickening. In vitro studies by this group have demonstrated 
a dose-response relation (30) that was also enhanced by 
pretreatment with heparin For 48 h 1311. Another potentially 
important et&t of heparin is the inhibition of migration oi 
smooth muscle cells from the media to the intima (321. as up 
to 50% of the intimal smooth muscle cells actually never 
divide (33). This antiproliferative ffect is specific to heparin- 
like molecules in that other palyanions Fail to inhibit the 
proliferation. Low molecular weight dextrao. a compound 
with similar molecular weight and sulfate content as hetwin. 
was effective in inhibiting proliferation (34). The most potent 
inhibition amars to occur with oolysaccharides with 8 to IO 
residues (2ij. Subsequent studies 130) have suggested thal 
heparin-like substances may Function as naturally occurring 
regulators of smooth muscle cell prolifentmn. perhaps se- 
creted by endothelial cells, 
Several inwsrigarors 134.35) how skowz lhor rkr onripm- 
l$erutiw effects of beparin are disrinrr f otn its ontiwnpn- 
lanreffecrs. Nonanticoagulant heparin isobtained by passing 
hepatin through a Sepharose-antithrombin column. thus 
eliminating antithrombin binding Fragments of heparin. 
When compared with unfractionated and coagulant fractions 
of heparin, the nonanricoagulant fraction had the greatest 
inhibitory effect in the rat carotid artery. as assessed by 
intima to media thickness ratio. Low molecular weight 
heparin. by virtue of the smaller Fragments. also contains a 
high percent of this nonantirn?&nt Fraction. 
(36) demonurated that heparin is rapidly taken up by the 
cells and rhat it either blocks the transition to or acts very 
early in the S phase. Majesky et al. 137). using a rat carotid 
arterv miurv model. showed that he&n administration 
could be delayed for as long as 18 h-after balloon injury 
without any loss in its amiorolifermive effect. Thus. it does 
not appear to work thr”&h inhibition of platelet-derived 
growth factor or prevention of thrombus. 
The eorrent slody. This study $haws that enoxaparin in 
high d”,e t IO m&g per day) can reduce restenosis een after 
balloon angioplasty in this model. A nonsignificant rend 
toward less restenosis was seen at the extrapolated human 
dose of I mg!kg per day. The effects are more pronounced 
when cnoxaparin is given For 4 weeks. but the results For 2 
weeks of therapy are also significant. The histopalhologic 
analysis does not provide a clear answer as to how this e5ect 
IS atamed. Whether the results are due to a decrease in 
thrombus formation at the site of balloon inflation. a direct 
effect on cellular proliferation or lome other mechanism 
cannot be determined From the present data. The efficacy of 
enoxarxarin given for only 2 weeks does not exclude an 
antiprblifen& effect b&we angiographic evidence of 
restenosis develops within 4 weeks in this model. In the rat 
carotid artery model. commitment of a cohort OF smooth 
muscle cells to proliferation takes piwe within rhe Is1 3 days 
after balloon injury (32). In this rabbit model. with an& 
plasty of obstructive stenoses. a more significant vessel wa9 
injury results (15). Thus. it is likely that the stimuli for 
proliferation are present For a longer period after the injury. 
although they are still likely to occur relativel: early in the 
time course of restermsis. Heparin has known lipdytic 
effects 120). but given the histologic evidence of predomi- 
nantly foam cell esions in both treatment and control groups 
and the marked elevation in cholesterol in this model. it is 
unlikely that the beneficial &cts are mediated through 
lipoprotein lipase activation. Clarification of the mechudsm 
of action of enoxaparin awaits FuLlher study. 
Tbpfindinps “frhis study support /he use ofinkibitors of 
r~twinrimol proliferkm ro pr~amr reslenosis. The “se of 
agents with alternative mechanisms of smooth muscle cell 
inhibition is also under active investigation. One such agent. 
cilaraprii. has been show” 138) to have a” antiproliferative 
effect in a rat carotid artery injury model. Of note is that the 
combination of this angiotensin-convening enzyme inhibitor 
and hepann had an effect greater than that see” with either 
agent alone. 
Limitations. There are several limitations of the current 
animal study. First, there is no ideal model for restenosis 
after human coronary angioplnsty. The histologic evidence 
of rewnosis in this model contains a much more prominent 
Foam cell component than is seen in humans. reRecting tk 
markedly elevated cholesterol levels. and thus the benefit 
seen io this model may not reflect the effect in human 
patients. Second. the dose effective in rabbits is IO times the 
usual human dose on a per kilogram basis. However. there is 
no means of assessing the relation between the antiprolifer- 
alive effects and in viva human dose. Thus. it may be 
hazardous to extrapolate a dose that is effective in an animal 
model to an ctTcc,ive do% in humans. Although ,he use of 
any one agcn, ,o completely inhibit rcslcnosis may require 
high doses that arc poorly tolerafed. as shown by others (38). 
the combination of different agents with complementary 
etTccts may allow the use of lower doses ,hat have additive 
or even synergistic effects on the inhibition of restenosis. 
Ahernatively. the use of a local delivery system may provide 
the means to achieve high local concentralions of drugs a, 
the si,c of vascular injury withou, the potential adverse 
systemic effects. The adventitial adminislralion of hcparin 
has been shown (39) lo reduce smooth muscle cell prolifer- 
ation in the injured ra, carotid model. 
Conclusions 
To dare. only one clinical study (40) of heparin after 
angioplasty has been reported. In ihis trial. intravenous 
hcparin for 18 to 24 h after uncomplicated angioplasty failed 
to reduce the incidence of restenosis. However. the brief 
administration of heparin after angioplasty may not ade- 
quately inhibit smomh muscle cell proliferation because this 
process may begin several days after the injury. Currently. a 
multicenter trial of enoxaparin for the prevention of resteno- 
sis after angioplasty (ERA trial) is ongoing in nine centen A 
total of400 patientr received 30 mg of enoxaparin or placebo 
by subcutaneous ir,jcc,ion daily for I month and will undergo 
repeal cardiac catheterization at 6 months. The primary end 
point ofthe study is restenosis as de!ermined by quantitative 
angiographic techniques. 
In conclusion. this study shows that a high dose of 
enoxaparin given for either 2 or 4 weeks after iliac angio- 
plasty significanlly xduces reslenosis in ,he alherosclerotic 
rabbit. Attempts at preventing restenosis to date have fo- 
cused on the initial steps in the process. such as spasm and 
platelet deposition. This study suggesfs ,hst inhibition of 
later stages in the process can be highly effective in the 
prevenlion ofreslenosis. The clinical utility ofcnoxaparin to 
prevent rcstenosis in humans will he determined by the 
results of the ongoing double-blind, randomized. placeho- 
conlrolled trial. 

